Bone Abstracts

Hip fractures are a major cause of burden in terms of mortality, disability, and costs. In Ireland, 3000 hip fracture occur annually and is expected to increase over the coming years1. Estimated cost of hip fractures is &z.euro;14 300/admission2. Outpatient non-attendance is a source of inefficiency, wasting time, resources and lengthens waiting lists. Non attendees have a significant negative impact on productivity, their own care and resources. In 2008,...

The effect of recombinant parathyroid hormone therapy as an anabolic agent has delivered great success in the treatment of osteoporosis. Although a treatment response is still defined in DXA terms, initial scans can fail to detect an increase in BMD since the collagen deposited in bone may not yet have mineralized. It is key therefore that an early response is detected biochemically and the physician can be reassured that the bone is not adynamic, the patient is compliant and ...

Introduction: Hip fracture is a significant health problem with 25–30% occurring in men. Outcome differences between the genders have been documented, particularly mortality rates.Aim: To prospectively investigate outcomes of elderly hip fracture patients regarding mortality, recovery of function, quality of life, incidence of osteoporosis, osteoporosis knowledge, medication adherence, nutritional status and fear of falling.Me...

Introduction: Osteoporosis affects the bones causing weak or brittle bones and increasing the risk of fracture. Efficacy of anti-osteoporotic treatment is based on drug potency and adherence and persistence. Teriparatide (TPTD) is the first anabolic agent developed for the treatment of osteoporosis. It is usually given as a daily subcutaneous injection for a two-year treatment course.Aim: To evaluate adherence and persistence to TPTD treatment in patient...